Remedium Capital Partners, LLC — 13F Holdings

2026 Q1  ·  6 Positions

2026 Q1 Portfolio Activity

In 2026 Q1, Remedium Capital Partners, LLC maintained a portfolio of 6 distinct positions. They heavily accumulated shares in Damora Therapeutics Inc, increasing the position by 1597.9%.
Position History hover any row below to update
Loading…
PCA Score Concentration Risk
Risk ENB
Total Positions
6
Quarter
2026 Q1
Top Holding
SYRE (30.1%)
Top 10 Concentration
100.0%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-6 of 6

Remedium Capital Partners, LLC Full Holdings List — 2026 Q1

Stock History Sector / Type Port % Prev % Rank / Prev Conviction Change % Change Influence Shares Mkt Value Avg Cost Price Held 1st Owned Source Source Date Date Reported
SYRE
Spyre Therapeut...
Healthcare 30.09% 28.03% #1
Prev: #1
8.5 451,096 31.0%
P
S
1,907,327 $96,205,574 2025 Q4 13F Filing 2026-03-31 2026-05-13
ORKA
Oruka Therapeut...
Healthcare 28.98% 27.64% #2
Prev: #2
8.0 336,701 21.7%
P
S
1,889,115 $92,661,091 2025 Q4 13F Filing 2026-03-31 2026-05-13
GLTO
Damora Therapeu...
Healthcare 16.57% 1.63% #3 3
Prev: #6
8.0 1,925,000 1597.9%
P
S
2,045,473 $52,977,750 2025 Q4 13F Filing 2026-03-31 2026-05-13
APGE
Apogee Therapeu...
Healthcare 15.36% 25.88% #4 1
Prev: #3
5.5 no change no change
P
S
583,591 $49,120,854 2025 Q4 13F Filing 2026-03-31 2026-05-13
JBIO
Jade Bioscience...
Healthcare 6.93% 14.30% #5 1
Prev: #4
4.3 no change no change
P
S
1,577,750 $22,167,388 2025 Q4 13F Filing 2026-03-31 2026-05-13
N/A
Crescent Biopha...
Unknown 2.08% 2.52% #6 1
Prev: #5
1.8 no change no change
P
S
361,250 $6,636,163 13F Filing 2026-03-31 2026-05-13
Showing 1-6 of 6 holdings

Unlock Full Remedium Capital Partners, LLC Analysis

PRO subscribers get access to all historical quarters, Excel/CSV exports, Portfolio Concentration Analytics (PCA), and Risk-Based ENB.

Full Historical Quarters
Excel & CSV Export
PCA & Risk-Based ENB
Auto Cost Basis
Position Change Alerts
Price-Held Analytics
Full history →